stratification tools have been developed to identify patients with micrometastatic disease in an effort to determine those who may potentially benefit from lymphadenectomy [6, 7] . The inclusion of lymphadenectomy into the operative plan adds time and necessitates intensified handling of the great vessels. For lymphadenectomy to be incorporated in the treatment algorithm, there should be an established benefit, be it staging or therapy. We review the literature to understand the historical basis, risk assessment, use and development of nodal templates, and therapeutic benefits associated with the use of lymphadenectomy in the management of renal cell carcinoma.
Introduction
radical nephrectomy remains a mainstay in the management of renal cell carcinoma since it was initially popularized by robson over four decades ago [1] . The role of lymphadenectomy in the management of renal cell carcinoma continues to be evaluated. although the utility of lymphadenectomy in staging has been well established [2, 3] , the therapeutic benefit remains controversial [4, 5] . risk 1 3
Historical perspective
The seminal work that established the modern surgical approach to renal cell carcinoma was published by robson et al. [1] . They reported on 88 patients who underwent surgery from 1949 to 1964. Follow-up ranged from 3 to 15 years with 97.7 % of the patients being followed out to 15 years or death. patients who underwent radical nephrectomy with lymphadenectomy were found to have a significant survival benefit. The researchers attributed this to three aspects of the operation: "early ligation of the renal artery, removal of the entire perinephric fat envelope without its incision, and removal of the lymphatic drainage system [1] ." among patients in this series, all underwent lymph node dissection from the crus of the diaphragm to the aortic bifurcation with inclusion of para-aortic and paracaval lymph nodes. The pathologic lymph node involvement in this series was 22.7 %. Due to the work of robson and colleagues, the role of lymphadenectomy evolved as an integral component in the modern surgical approach.
Establishing risk for lymph node disease
The therapeutic benefit of lymphadenectomy has not been well established and no benefit may be expected for patients without lymph node involvement. Selective use in patients at greatest risk for the development of nodal disease is the most judicious approach. To identify such patients, Blute et al. [7] reviewed the Mayo clinic experience from 1997 to 2000. In all, 1,652 patients with unilateral non-metastatic sporadic clear cell renal cell carcinoma underwent radical nephrectomy. The overall rate of nodal disease in this group was 3 % (solitary node) and 1 % (multiple nodes), respectively. a multivariate logistic regression analysis was completed. Statistical significance for increased risk of nodal disease was noted in patients with nuclear grade 3-4, presence of sarcomatoid histology, tumor size ≥10 cm, tumor stage T3 or T4, and the presence of tumor necrosis [7] . In patients with two of these features, the risk of nodal disease was established to be 4.4 %. In patients with all five features, the risk was determined to be 53.3 %. Less than two features were associated with under a 1 % risk for the development of metastatic disease in the lymph nodes. Based upon these findings, the Mayo group established a threshold of two or more risk features in order to recommend lymphadenectomy. Interestingly, 66 % of patients in this study had radiographically enlarged nodes, while the remainder had radiographically negative lymph nodes with micrometastatic disease. In this series, cT imaging may have helped better define the high-risk population. as a consequence, risk stratification tools such as that from the Mayo clinic are essential to identify true radiographic as well as micrometastatic lymph node disease [7, 12] . The retrospective design and the absence of a standardized template for lymphadenectomy were limitations of the study.
Studer et al. established the clinical value for cT imaging in establishing 95 % sensitivity for lymph nodes greater than 1.0 cm. In Studer's series, 42 % of lymph nodes meeting that size criteria harbored metastatic disease on surgical pathology [3] . Despite the high sensitivity for cT imaging lymph nodes can be enlarged secondary to inflammation secondary to tumor necrosis and yields a lower specificity.
Terrone et al. [2] reviewed pathological reports of 735 nephrectomies in order to establish the prognostic value of lymphadenectomy. Total number, number positive, location, and density of lymph nodes were recorded. The mean number of nodes removed was 13 (range 1-35) with a median number of positive nodes of 3 (range 1-18). The rate of positive lymph nodes was 14.2 % with a 5-year cancer-specific survival in node-positive patients of 18 %. They found no difference between pN1 and pN2. The number of lymph nodes removed had no impact on survival in node-positive patients. However, in patients with greater than four positive lymph nodes, this was a significantly worse prognostic indicator as compared to those with less than or equal to four positive nodes.
Dimashkieh et al. retrospectively reviewed the records of 2,076 patients who underwent radical nephrectomy for unilateral sporadic renal cell carcinoma. They found 34 patients with a single nodal metastasis (pN1) and 35 with multiple (pN2). pathologic features of the lymph nodes were recorded including number, percent positive, grade, necrosis, size, and extranodal extension. although the pathologic nodal classification pN1 versus pN2 was not a significant predicator of death from renal cell carcinoma, patients with extranodal extension of disease were twice as likely to experience cancer-specific death [13] .
Lymphadenectomy and mapping
Interest and investigation into the progression of disease through the lymphatic system of the retroperitoneum dates back to the work of parker [14] . parker's work established drainage patterns from the right kidney through the precaval, retrocaval, and interaortocaval nodal groups. Similarly, drainage from the left kidney was observed to be through the para-aortic, preaortic, and retroaortic nodal groups. Historically, lymphadenectomy has been performed in order to stage and control the disease in the retroperitoneum. a variety of techniques have been used. Hilar dissection is a technique that limits resection to the nodes surrounding the renal vessels. Regional lymphadenectomy has included the hilar as well as the paracaval (right) and para-aortic (left) nodal groups. Extended lymphadenectomy includes hilar, precaval, paracaval, retrocaval, interaortocaval, and preaortic lymph nodes for right-sided tumors; and hilar, preaortic, para-aortic, retroaortic, interaortocaval, and precaval nodal groups for left-sided tumors. cephalad and caudal limits extend from the crus of the diaphragm to the iliac arteries.
The decision to perform lymphadenectomy and its extent has been the subject of much debate. as we have noted previously, Blute et al. [7] established five risk features associated with the development of lymph node disease involvement. However, the optimal lymphadenectomy technique remained undefined. In an effort to better understand the relationship between the established risk factors and the pattern of disease progression, crispen et al. [12] set out to identify the locations of the nodal metastases and develop a standardized template for lymphadenectomy for high-risk patients. expectedly, crispen found that the location of the lymph node metastases was related to the side of the primary tumor. Interestingly, of the 64 patients with retroperitoneal nodal disease, 29 (45 %) had negative perihilar lymph nodes. Stepwise progression was observed in the nodal groups on both sides and no "skip lesions" were observed. In patients with right-sided tumors, no para-aortic nodes were positive without first observing metastases in the paracaval and interaortocaval nodal groups. Similarly, leftsided tumors demonstrated no paracaval nodal metastases without the presence of tumor in the para-aortic or interaortocaval nodal groups (Figs. 1, 2) [12] . These findings are consistent with prior studies of the suspected primary lymphatic drainage in the retroperitoneal nodal groups [14, 15] .
Based upon their work, crispen et al. made several important observations. First, they noted that in patients with micrometastatic nodal disease the hilar lymph nodes on the ipsilateral side of the tumor are negative 45 % of the time. This is a strong indicator that hilar nodal sampling alone is inadequate and may understage the disease. Second, they noted a predictable distribution of landing zones across the retroperitoneum given the side of the primary tumor. Based upon these observations, they recommended removal of all lymphatic tissue within the primary landing zones as well as a standardization of the resection template for patients with two or more high-risk features. For rightsided tumors, the authors recommended removal of the paracaval and interaortocaval lymph nodes from the crus of the diaphragm to the common iliac arteries. Similarly, for left-sided tumors, they recommended removal of the para-aortic and interaortocaval lymph nodes with the same cephalad and caudal limits [12] . In the case where disease is confirmed in the retroperitoneum, bilateral templates should be completed. a limitation of the work by crispen et al. is the inclusion of patients whose computed tomography images have clinically suspicious lymph nodes [16] . 
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The evidence for and against lymphadenectomy
The european Organization for research and Treatment of cancer (eOrTc) Genitourinary Group initiated a prospective randomized controlled trial in 1988 in order to evaluate the therapeutic value of lymphadenectomy [17] . patients were randomly assigned to undergo a radical nephrectomy alone or a radical nephrectomy plus a complete lymph node dissection. The primary end point of the trial was duration of survival. patients were excluded if clinically detectable metastatic disease was noted. Lymphadenectomy extended from the crus of the diaphragm to the bifurcation of the great vessels. For right-sided tumors, dissections of the paracaval, precaval, postcaval, and interaortocaval nodes were performed. For left-sided tumors, dissections of the left para-aortic, left diaphragmatic, and preaortic nodes were performed. Lymph node sampling rather than formal complete lymphadenectomy was performed in patients randomized to the "nephrectomy-only" treatment group who were found to have an enlarged lymph node intraoperatively. Between May 1988 and September 1991, a total of 772 patients were randomized to radical nephrectomy alone (n = 389) or nephrectomy plus lymphadenectomy (n = 383). The complication rates were similar in the two groups. positive lymph nodes were detected in 14/346 (4 %). No difference was detected in overall survival, progression-free survival, or time to progression. The authors concluded that lymphadenectomy did not increase morbidity, but nor did it improve overall or progression-free survival. The low number of patients with metastatic lymph nodes made detecting a difference more difficult. This is possibly related to the high negative predictive value of preoperative computed tomography staging scans as patients with abnormal studies were excluded from the trial. additional limitations of this study include incomplete data to assess the adequacy of lymph node dissection, and a cohort comprised of 71 % low stage (T1-T2) and 73 % low grade (G0-G2) patients.
In contrast, several retrospective studies have noted potential therapeutic benefit to lymphadenectomy in higher risk populations. pantuck et al. [18] performed a singleinstitution retrospective review of the experience at the University of california at Los angeles. They identified 900 patients who underwent radical or partial nephrectomy between 1989 and 2000. Lymphadenectomy information was available for 798 of these patients. The extent of the lymphadenectomy was not standardized. The end point of interest was survival time. The median follow-up was 30 months, and the median time to death was 16 months. The patients were stratified into four groups: N0M0 (n = 535; 59 %), N + M0 (n = 43; 5 %), N + M1 (n = 86; 9 %), N0M1 (236; 26 %). Median survival was best in patients without nodal or metastatic disease, was similar in patients with either nodal or metastatic disease, and was significantly worse in patients with both nodal and metastatic disease. For patients without clinically evident nodal disease, survival was not impacted by lymphadenectomy. However, in patients with distinct clinical nodal disease, survival was positively impacted by 5 months in patients undergoing cytoreductive nephrectomy and postoperative immunotherapy [18] . In multivariable analysis of lymph node-positive patients, higher grade and absence of lymph node dissection were statistically significant predictors of decreased survival [18] .
Vasselli et al. [19] retrospectively reviewed the charts of 154 patients treated at the National Institutes of Health Surgery Branch between 1985 and 1996 for metastatic renal cancer who underwent cytoreductive nephrectomy in preparation for systemic immunotherapy. Of this cohort, 82 were without clinically evident nodal disease preoperatively (median survival 14.7 months), and 72 had at least 1 cm of distinct lymphadenopathy (median survival 8.5 months). patients with clinical lymphadenopathy were subdivided into four groups: completely resected (n = 13), incompletely resected (n = 29), unresectable (n = 5), or unknown volume resected (n = 25). No difference in survival was noted between patients with completely resected retroperitoneal lymphadenopathy and those without preoperative clinical lymphadenopathy [19] . although patients with clinical lymphadenopathy had relatively shorter median survival, complete resection appeared to offer benefit in this study.
Whitson et al. conducted a population-based study using the Surveillance, epidemiology, and end results database (Seer) [20] . The study group consisted of 9,586 patients who had undergone radical or partial nephrectomy with lymphadenectomy between 1988 and 2006. Median follow-up was 3.5 years (range 1.4-6.8). Of the patients 2,382 (25 %) died from renal cell carcinoma, 1,644 (20 %) with lymph node-negative disease, and 736 (58 %) with lymph node-positive disease. a cox regression analysis was conducted to determine the association between lymph node status and number of lymph nodes with cancer-specific survival. In patients with negative lymph nodes, there was no effect on disease-specific survival with increasing extent of lymphadenectomy. However, an absolute survival increase of 10 % (39-49 %) at 5 years was seen in patients with one positive lymph node in whom ten lymph nodes were removed. This study showed an association between extent of lymphadenectomy and improved disease-specific survival in a population-based sampling of patients with nonmetastatic lymph node-positive renal cell carcinoma. This suggests that patients at high risk for disease should undergo extended lymphadenectomy.
Sun et al. [21] reanalyzed the Seer data initially evaluated by Whitson et al. [20] . In the initial analysis by Whitson tumor grade information was missing in 2,916 (28 %) patients. Sun et al. chose to use data from 1988 to 2008 in which 10,596 patients were available for analysis. The data were divided into three subgroups. The first subgroup reapplied the methodology as Whitson et al. (Imputated group). The second subgroup was identified by excluding all patients with unknown tumor grade information. The final subgroup identified patients with missing tumor grade as a separate sub category. The primary variable of interest was number of lymph nodes removed, and the primary end point of interest was cancer-specific mortality. Overall, 2,916 (28 %) had missing tumor grade information. In a multivariable analysis, the extent of lymphadenectomy was associated with a significant protective effect on the cancer-specific mortality in patients with node-positive disease after imputation. conversely, the extent of lymphadenectomy was not significantly associated with a lower cancer-specific mortality after excluding patients with a missing tumor grade or in patients where tumor grade was used as a sub category. reanalysis of the Seer data failed to identify a survival benefit with increasing extent of lymphadenectomy. The authors concluded that the handling of missing data using statistical methodology such as imputation may bias the sample and result in statistically significant associations [21] .
Delacroix et al. [22] retrospectively reviewed the institutional nephrectomy database at the University of Texas M.D. anderson cancer center. In a series of 2,521 patients, 68 were found to have had radical nephrectomy and lymphadenectomy with pathologic node-positive disease in the absence of detectable metastases. Lymphadenectomy was not standardized during the study period but all patients were completely resected of lymphadenopathy. at a median follow-up of 43.5 months, 22.1 % of patients were free from recurrence, 72.1 % experienced recurrence, and 5.8 % died within 60 days before restaging could be accomplished. On multivariate analysis, overall survival was significantly improved in patients with ecOG performance status of 0, pathologic N1 versus N2, absence of sarcomatoid features, and papillary histology [22] . In this series, 22.1 % of patients experienced durable survival following lymphadenectomy supporting its use.
Itano et al. [23] retrospectively reviewed the Mayo clinic experience from 1970 to 1998. From a group of 1,737 patients with T 1-3 N 0 M 0 , 30 patients (1.8 %) were found to have an isolated recurrence in the renal fossa at 5 years. The mean follow-up time was 3.3 years with a mean time to recurrence was 2.8 years. In patients with a renal fossa recurrence 12 (40 %), patients presented on routine follow-up and 18 (60 %) were symptomatic. patients were sub stratified into three groups: observation alone, systemic medical therapy, and surgery alone or with additional medical therapy. There was no perceptible difference between patients presenting with and without symptoms. However, the 5-year survival for observation (13 %), adjuvant medical therapy (18 %), and surgical resection with or without medical therapy (51 %) (p ≤ 0.02) favored resection of the isolated renal fossa recurrence. although a rare occurrence, surgical extirpation of the recurrent disease improved survival in this series.
Boorjian et al. [24] retrospectively reviewed the experience from the Mayo clinic. They identified 15 patients who had undergone radical nephrectomy and developed an isolated metachronous recurrence in the retroperitoneum in the absence of metastasis. No standard template was used for lymphadenectomy, and all patients were completely resected at a median of 10.3 months following initial surgery. patients were observed after resection of the recurrence without the use of adjuvant systemic therapy. In this series, patients who underwent resection of an isolated retroperitoneal recurrence demonstrated survival similar to those patients who underwent resection of a solitary metastatic lesion. The retrospective nature, the lack of standardized lymphadenectomy, and small number of patients that met the study criteria are weaknesses of this series.
Feuerstein et al. [25] retrospectively reviewed patients with ≥7 cm tumors who underwent partial or radical nephrectomy at the Memorial Sloan Kettering cancer center. Of 524 patients, 164 experienced recurrence of disease and 197 died from all causes. Median follow-up was over 5 years, with 334 (64 %) patients having a lymph node dissection with positive nodes in 26 (8 %). For patients who did and did not have a lymph node dissection the 5-year recurrence-free survival was 64 and 77 %, respectively. Similarly, the 5-year overall survival was 75 and 78 %, respectively. Lymphadenectomy did not predict recurrence or survival. However, node-positive disease was associated with a recurrence and mortality supporting the staging role of lymphadenectomy.
emerging paradigms for the management of advanced renal cell carcinoma employing neoadjuvant targeted systemic may improve the benefit with resection of lymph node metastatic disease. Karam et al. [26] performed a multi institutional retrospective review of 21 patients with metastatic renal cell carcinoma of any histology that underwent nephrectomy followed by one cycle of targeted systemic therapy than metastasectomy to remove residual disease. patients were treated between October 2004 and august 2009. Median age was 56.9 years, and median follow-up was 109 weeks. Metastasectomy sites included the retroperitoneum (12), lung (6), adrenal (2), bowel (2) , and one each in the mediastinum, bone, brain, and inferior vena cava. Four patients had multiple sites. Twenty patients had viable tumor in the resection and two were without tumor. all 22 patients had complete resections. at 105 weeks postoperatively, 21 patients were alive. consolidative metastasectomy/lymphadenectomy seemed to offer benefit and was recommended based upon this small series [26] .
A predictive model for lymphadenectomy
Despite the numerous studies aimed to identify the value of lymphadenectomy, the identification of when and in whom to perform lymphadenectomy remains unresolved. citing a limitation of the work by crispen et al. [12] as limited to information that is only available by intraoperative frozen section pathological analysis, capitanio et al. [27] set out to develop a predictive model based entirely upon preoperative assessment. They performed a single-institution retrospective review of 1,983 patients who underwent partial (n = 712) or radical (n = 1,271) nephrectomy between 1987 and 2011. among patients with clinically node-negative disease (n = 1,727), 672 underwent lymphadenectomy (hilar = 333, regional = 232, extended = 107). Median follow-up was 67.5 months. Median overall and cancerspecific survival at 5 and 10 years, respectively, was as follows: OS = 82.7/77.3 %, and cSS = 73.8/60.7 %. Lymph node progression was observed in 82 patients (4.1 %). Of patients with progression, 17 (20.7 %), 38 (46.3 %), and 27 (32.9 %) had pNx, pN0, and pN1 disease at surgery. Using clinical characteristics that were available before surgery (tumor stage, clinical nodal status, presence of metastases, and tumor size) they developed a model aimed to predict lymph node invasion and/or progression. The accuracy discrimination of their nomogram was determined to be 86.9 %. When using a threshold of 3 % chance of lymph node invasion the sensitivity, specificity, and negative predictive value of this nomogram was 92.6, 53.7, and 98.7 %, respectively. The major advantage to the use of this nomogram is the absence of a need for intraoperative frozen section pathologic analysis to decide upon the performance of a lymphadenectomy. Despite the value and strong fit of this predictive model, the retrospective nature, potential for selection bias in medical record selection, non-standardization of lymphadenectomy templates, the incomplete knowledge of lymph node progression, and the lack of external validation of this cohort are limitations of this study.
When to perform lymphadenectomy
It is well established that lymphadenectomy improves staging in renal cell carcinoma. However, there is currently level one evidence that suggests that there is no therapeutic benefit in a low-risk population [17] . Based upon the work that we have presented, the value of lymphadenectomy appears to depend largely upon patient selection. Blute et al. [7] established a group of high-risk features predictive of the development of micrometastatic disease. crispen et al. went on to use these same risk factors to establish the pattern of disease progression through the retroperitoneum. Based upon this work and the pattern of disease evolution, standardized surgical templates were recommended [12] . Unfortunately, the work from the Mayo clinic depended upon intraoperative frozen section analysis to compute these risk factors. although standard practice at the Mayo clinic, many institutions lack this rapid detailed intraoperative pathologic analysis. capitanio et al. [27] developed a predictive nomogram based entirely upon factors known during the operative planning phase. Bex et al. [28] have recently explored the use of sentinel lymph node identification in patients with clinically node-negative renal cell carcinoma and have had some initial success. However, more studies need to be performed to define the role of this technique in the clinical algorithm.
When patients are known to have clinically negative nodal invasion, there was not a statistically significant benefit with lymphadenectomy in the eOrTc trial. However, the groups lead by pantuck et al. [18] , Vasselli et al. [19] , Whitson et al. [20] , and Sun et al. [21] all detected a benefit from lymphadenectomy in patients with clinical evidence of disease. In these patients, lymphadenectomy should be recommended. Delacroix et al. [22] demonstrated that in patients with either clinically positive lymph node disease or at least two high-risk features as described in the Mayo series, an overall and disease-specific survival benefit was obtained. The groups led by Itano et al. [23] , Boorjian et al. [24] , and Karam et al. [26] demonstrated survival benefit when resecting a recurrence in the retroperitoneal lymph nodes, the renal fossa or complete resection of limited metastatic lesions, respectively. However, the complication rate in all three series was high suggesting reoperation offers increased morbidity [23, 24, 26] . eOrTc demonstrated equivocal morbidity when lymphadenectomy was performed at the time of nephrectomy providing further evidence that lymphadenectomy at initial surgery offers the best possible opportunity for disease control at the lowest morbidity cost.
Conclusions
Lymphadenectomy improves staging for renal cell carcinoma. Level one evidence suggests that there is no survival benefit for clinical node-negative disease. However, retrospective analyses suggest that there is benefit in patients with clinical node-positive disease, in patients who have high-risk features for micrometastatic disease, or in patients with an isolated retroperitoneal nodal recurrence. preoperative and intraoperative risk assessment can assist with the decision to perform lymphadenectomy. Lymphadenectomy adds little additional morbidity when performed at nephrectomy and can be completed in a timely and innocuous manner in centers of excellence. When performing a lymphadenectomy, a standardized template should be utilized and resection of all lymphatic tissue in the primary landing zones is mandatory if one is to maximize the survival benefit and to definitively secure the retroperitoneum.
